Immuron (ASX:IMC) has received $1,469,763 in a cash refund from a Research & Development programs during 2015 in the form of tax concessions.
The Incentive refund is a tax concession for Australian biotechnology companies to fund ongoing research and development pipelines and advance promising programs.
Immuron’s marketed product, Travelan, is for the prevention of travellers’ diarrhoea, while its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH.
The company focuses on commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases.
Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.